UNSPSC 51422510: Oxisopred

This classification denotes a therapeutic glucocorticoid with the molecular formula C21H28O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0C39YBM73T, chemically known as 11beta,17,21-trihydroxy-b-homo-a-norpregn-1-ene-3,6,20-trione but generally known as oxisopred, which bears US NIH Compound Identifier 3047809. European Medicines Agency schedules Oxisopred in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09538MIG.

UNSPSC 51422510 Oxisopred is a Commodity code covering pharmaceutical products, specifically opioid antagonists and related drug-management systems procured by state and local health agencies. State and local governments buy naloxone (an opioid overdose reversal medication) and safe drug deactivation systems under this code, typically for community health programs, emergency response, and substance-abuse intervention initiatives. The issuing bodies include county health departments and state health and human services agencies that manage pharmacy benefit programs and community health deliveries. Procurement typically occurs through competitive bidding processes (IFB notices) for fixed quantities with annual renewal options, with vendors required to meet standard compliance certifications including E-Verify, drug-free workplace attestations, and insurance requirements.

Recent activity centers on Florida and Texas. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its Community Health Building in Sanford, with a response deadline of July 26, 2023, and a two-year initial term with one-year renewal option. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather vendor capabilities regarding direct-to-manufacturer prescription programs, including naloxone and related pharmaceuticals, with a response deadline of April 3, 2026—this RFI serves as preliminary market intelligence before a formal RFP. Neither solicitation specifies set-aside designations for disadvantaged enterprises.